<DOC>
	<DOCNO>NCT00359619</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . Indeed , certain oncogenic type HPV infect cervix ( part uterus womb ) . This infection may go away , go away ( call persistent infection ) , lead woman long period time cancer cervix . GlaxoSmithKline Biological 's developed HPV vaccine oncogenic type HPV-16 HPV-18 formulate AS04 adjuvant ( control vaccine ) also evaluate novel HPV vaccine formulation . This study evaluate long-term immunogenicity safety novel GSK Biological 's vaccine approximately 376 subject receive novel vaccine control vaccine administer primary study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Human Papillomavirus Vaccine Immunogenicity Safety Trial Young Adult Women With GSK Biologicals Novel HPV Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A female enrol study 102115 receive three dos vaccine . Written inform consent obtain subject prior enrolment . Use ( plan use study period ) investigational nonregistered product offlabel use license product ( drug vaccine ) . Chronic administration immunosuppressant immunemodifying drug occur less three month prior blood sampling . Administration immunoglobulins and/or blood product within three month precede blood sampling . Planned administration HPV vaccine , foreseen study protocol , study period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV vaccine</keyword>
</DOC>